Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Neoplasms, Plasma Cell × Plasma cell × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 24 Recurrence 3 Thyroid Carcinoma, Anaplastic 1 Smoldering Multiple Myeloma 1 Nonseminomatous germ cell tumor 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Glioma 1 Gastrointestinal Stromal Tumors 1 Biliary Tract Neoplasms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Pfizer

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡